Skip to content

Trial Summary

This phase II study will investigate the activity and safety of radionuclide 177Lu-PSMA therapy versus 177Lu-PSMA in combination with Ipilimumab and Nivolumab in patients with metastatic castrate resistant prostate cancer (mCRPC).



ACTRN/NCT /ethics:


Scientific title:

Phase II Study of Radionuclide 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With MetastaticCastration Resistant Prostate Cancer (mCRPC)

Sponsor / Cooperative group:

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Trial & Patient Characteristics

Cancer TypeProstate
Trial TypeTreatment
PhasePhase II
Age Range18 Years and older
Tumour Stream -
Cancer StageMetastatic or Widespread
Anticipated Start Date2022-04-29
Anticipated End Date2024-12-01

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Phone08 7074 2342
Principal InvestigatorDr Hsiang Tan
Recruitment StatusRecruiting